Fundus Photograph Reading Center

Leader in Ophthalmic Image Evaluation since 1970

We are the core imaging lab within the University of Wisconsin – Madison Department of Ophthalmology and Visual Sciences studying diabetic retinopathy, age-related macular degeneration, uveitis and other ophthalmic diseases.The Fundus Photograph Reading Center (FPRC) was founded on the enduring principles of intellectual honesty, quality, relevance, innovation and staff satisfaction.

We serve a wide range of academic institutions, foundations, pharmaceutical companies and biotech firms including the National Eye Institute, National Institute of Diabetes and Digestive Kidney Diseases, Diabetic Retinopathy Clinical Research Network and the Department of Defense.

 

Services

For early phase clinical trials, we offer a streamlined approach tailored to the needs of the study and sponsor.

  • Consultation on protocol design
  • Project management
  • Image analysis
  • Certification and regulatory compliance

 

 

Workflow:

  • Consultation on protocol design
  • Defining ocular disease outcomes
  • Study protocol/start-up training
  • On Site/off Site and web based training on imaging protocols
  • Certification of photography equipment and operators
  • Project management
  • Electronic upload of digital images
  • DICOM conversion
  • Inventory tracking
  • Query monitoring
  • Image quality monitoring and reporting
  • Reproducibility reports for evaluation data
  • Collaboration on manuscript preparation
  • Storage and archival of study images

Evaluation Types

  • Diabetic retinopathy
  • Age-related macular degeneration
  • Macular Edema
  • Vein Occlusion
  • Infectious and non-infectious Uveitis
  • Cytomegalovirus retinitis
  • Lens opacities
  • Glaucoma and neurodegenerative diseases
  • Safety studies to monitor toxicity

Image Evaluations

  • Optical Coherence Tomography (quantitative and layer analysis)
  • Fundus autofluorescence (SLO and camera-based)
  • Color fundus photography
  • Fluorescein and ICG angiograms
  • Red reflex, retroillumination and slit lamp lens photographs

Regulatory Compliance

  • Independent Quality Assurance workgroup, reporting directly to the General Manager
  • FPRC Documentation is compliant with ICH (International Conference on Harmonisation) guidelines and global regulatory requirements.
  • FPRC developed software is compliant with 21 CFR Part 11, ICH and other applicable global regulatory requirements.
  • FPRC staff are trained in HIPAA, human subjects and regulatory compliance and follow a detailed set of policies and standard operating procedures (SOPs).
  • Expert FDA hearing support

Imaging

All imaging technicians and equipment participating in any of our studies are required to be certified by the UW-FPRC for each specific study and each specific procedure within that study, prior to submitting study participant images.

ACTIVE GRANTS

COMING SOON

recent publications and NEWS

Sensorineural Impairments, Cardiovascular Risk Factors, and 10-Year Incidence of Cognitive Impairment and Decline in Midlife: The Beaver Dam Offspring Study.

Jan 11 2019 // PubMed ID: 30629132 Author(s): Schubert CR, Cruickshanks KJ, Fischer ME, Pinto AA, Chen Y, Huang GH, Klein BEK, Klein R, Pankow JS, Paulsen AJ, Dalton DS, Tweed TS. Sensorineural Impairments, Cardiovascular Risk Factors, and 10-Year… Read More

Sensorineural Impairments, Cardiovascular Risk Factors, and 10-Year Incidence of Cognitive Impairment and Decline in Midlife: The Beaver Dam Offspring Study.

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

Dec 28 2018 // PubMed ID: 30589922 Author(s): Ip MS, Oden NL, Scott IU, VanVeldhuisen PC, Blodi BA, Ghuman T, Baker CW; SCORE2 Investigator Group. Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept… Read More

Month 12 Outcomes After Treatment Change at Month 6 Among Poor Responders to Aflibercept or Bevacizumab in Eyes with Macular Edema Secondary to Central or Hemiretinal Vein Occlusion: A Secondary Analysis of the SCORE2 Study.

Progressive Proptosis and Worsening Vision.

Dec 21 2018 // PubMed ID: 30570651 Author(s): Lucarelli KM, Raven ML, Lucarelli MJ. Progressive Proptosis and Worsening Vision. JAMA Ophthalmol. 2018 Dec 20. doi: 10.1001/jamaophthalmol.2018.5024. [Epub ahead of print] Journal: Jama Ophthalmology, Dec 2018 Read More

Progressive Proptosis and Worsening Vision.

Reproducibility and staging of 3D human retinal organoids across multiple pluripotent stem cell lines.

Dec 21 2018 // PubMed ID: 30567931 Author(s): Capowski EE, Samimi K, Mayerl SJ, Phillips MJ, Pinilla I, Howden SE, Saha J, Jansen AD, Edwards KL, Jager LD, Barlow K, Valiauga R, Erlichman Z, Hagstrom A, Sinha D, Sluch… Read More

Reproducibility and staging of 3D human retinal organoids across multiple pluripotent stem cell lines.

Oxidized Low-Density Lipoprotein and the Incidence of Age-related Macular Degeneration.

Dec 21 2018 // PubMed ID: 30572074 Author(s): Klein R, Lee KE, Tsai MY, Cruickshanks KJ, Gangnon RE, Klein BEK. Oxidized Low-Density Lipoprotein and the Incidence of Age-related Macular Degeneration. Ophthalmology. 2018 Dec 17. pii: S0161-6420(18)32430-8. doi: 10.1016/j.ophtha.2018.12.026. [Epub… Read More

Oxidized Low-Density Lipoprotein and the Incidence of Age-related Macular Degeneration.

Atrophy in Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 15.

Dec 07 2018 // PubMed ID: 30506012 Author(s): Domalpally A, Danis RP, Trane R, Blodi BA, Clemons TE, Chew EY; Age-Related Eye Disease Study 2 (AREDS2) Research Group. Atrophy in Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2… Read More

Atrophy in Neovascular Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report Number 15.

 CONTACT US

310 N. Midvale Blvd, Suite 205
Madison, Wisconsin 53705
Phone: (608) 262-1334
Fax: (608) 265-9509

EMAIL US